Scandinavian Journal of Rheumatology最新文献

{"title":"Diagnostic utility of the HAS-GCA score versus other Southend Giant Cell Arteritis Probability Score-ultrasound prediction models in giant cell arteritis.","authors":"H Wulff Schjødt Stoklund, It Tønder Hansen, K K Keller, P Therkildsen, E M Hauge, B D Nielsen","doi":"10.1080/03009742.2026.2724672","DOIUrl":"https://doi.org/10.1080/03009742.2026.2724672","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to validate the HAS-GCA score, a prediction model combining the Southend Giant Cell Arteritis Probability Score (SGCAPS) with ultrasonography (US) halo count, and compare its diagnostic utility with other prediction models combining SGCAPS with US scores for diagnosing giant cell arteritis (GCA).</p><p><strong>Method: </strong>: Treatment-naïve patients with suspected GCA were prospectively included in an observational cohort and underwent clinical assessment, including temporal artery biopsy (TAB) and pretreatment US and [¹⁸F]fluorodeoxyglucose-positron emission tomography/computed tomography. The clinical diagnosis was confirmed after 24 weeks. Baseline data were assessed to calculate SGCAPS. Three prediction models combining SGCAPS with US scores - halo score, OMERACT GCA ultrasound score (OGUS), and halo count - were applied to classify patients into low-, intermediate-, and high-probability categories of GCA. The ability of the prediction models to correctly classify patients into low- and high-probability categories, and the proportion of patients with intermediate probability requiring additional tests, were compared.</p><p><strong>Results: </strong>: GCA diagnosis was confirmed in 60/99 patients (61%). Prediction models based on halo count (HAS-GCA score), halo score, and OGUS had similar misclassification rates of 3%; HAS-GCA score had the lowest proportion of patients with intermediate probability (39% vs 47% and 59%, respectively).</p><p><strong>Conclusion: </strong>: The HAS-GCA prediction model reliably stratified patients with suspected GCA into low- and high-probability categories, enabling confidence in ruling in or ruling out the GCA diagnosis. However, almost half of the patients required further evaluation to establish a correct diagnosis.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-6"},"PeriodicalIF":1.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine for hypergammaglobulinaemic purpura of Waldenström in Sjögren's disease: a case series.","authors":"M B Thaler, Fth Ullrich, D Gailis, T Sonneck, A Skapenko, H Schulze-Koops","doi":"10.1080/03009742.2026.2727250","DOIUrl":"https://doi.org/10.1080/03009742.2026.2727250","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-3"},"PeriodicalIF":1.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors and factors associated with response in psoriatic arthritis with axial involvement: the APxis-IL12-23 study.","authors":"R Almodóvar, R Mazzucchelli, E Pérez-Fernández, E Trujillo, P Navarro, J Sanz-Sanz, B Joven, C Valero, R García-Vicuña, R Queiro, M Loredo, P Alvarez, L Martín de la Sierra López, D Castro Corredor, M Paulino Huertas, E Galíndez-Agirregoikoa, M L García Vivar, C Vergara-Dangond, A Terán, L Trives-Folguera, S Muñoz-Fernández, M Llop, M Moreno, J Gratacós, M Aparicio, L Mateo, L González, J A Pinto Tasende, C Fernández-Carballido, V Villaverde, C Marín, C Gómez, T Navío, F García Llorente, M Moreno, L Linares, M J Moreno, C Alvarez, I González, A Urruticoechea-Arana, J Ramírez, L Del Olmo, P Zarco, E Beltrán","doi":"10.1080/03009742.2026.2730765","DOIUrl":"https://doi.org/10.1080/03009742.2026.2730765","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the real-world effectiveness of two interleukin (IL)-23 inhibitors [guselkumab (GUS), risankizumab (RIS)] and an IL-12/23 inhibitor [ustekinumab (UST)] in patients with purely axial psoriatic arthritis (PsA) or mixed PsA (both axial and peripheral involvement), and identify response predictors.</p><p><strong>Method: </strong>In this retrospective multicentre study of patients treated with GUS, RIS, or UST, composite treatment response was defined as achieving a clinically important improvement (≥1.1) in Axial Spondyloarthritis Disease Activity Score-C-reactive protein (ASDAS-CRP) or ≥50% improvement from the initial Bath Ankylosing Spondylitis Disease Activity Index value (BASDAI50). Disease activity was evaluated using mixed models, and predictors were evaluated by modified Poisson regression.</p><p><strong>Results: </strong>In total, 167 patients were included: 87.4% had mixed PsA and 12.6% purely axial PsA. Baseline therapies were GUS (47.9%), RIS (13.2%), and UST (38.9%). Significant decreases in ASDAS-CRP and BASDAI (p < 0.001) occurred over 12 months. The total cohort's composite response rate at 12 months was 26.4%. Notably, 12 month response rates were numerically higher for IL-23 inhibitors (GUS 30.4%, RIS 40.0%) than for UST (15.7%), although these differences lacked statistical significance. Fulfilling Assessment of Spondyloarthritis International Society (ASAS) criteria [relative risk (RR) = 7.25, p = 0.023] and baseline ASDAS-CRP > 2.1 (RR = 2.30, p < 0.001) independently predicted clinical response.</p><p><strong>Conclusion: </strong>IL-23 and IL-12/23 inhibitors improved disease activity in a predominantly mixed PsA cohort. Although IL-23 inhibitors exhibited higher numerical response rates, statistical superiority over UST was not confirmed. Effectiveness strongly correlated with baseline disease burden and ASAS criteria.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-7"},"PeriodicalIF":1.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk and all-cause mortality across low-density lipoprotein cholesterol levels in seropositive rheumatoid arthritis: a nationwide cohort study.","authors":"J H Choi, J S Lee, C-N Son, B Ghang","doi":"10.1080/03009742.2026.2711548","DOIUrl":"https://doi.org/10.1080/03009742.2026.2711548","url":null,"abstract":"<p><strong>Objective: </strong>To assess cardiovascular disease (CVD) and all-cause mortality risk in patients with seropositive rheumatoid arthritis (RA) compared with matched controls, and examine whether low-density lipoprotein cholesterol (LDL-C) levels influence these risks.</p><p><strong>Method: </strong>This nationwide retrospective cohort study used Korean National Health Insurance Service data. Adults newly diagnosed with seropositive RA between 2010 and 2017 were matched 1:5 to non-RA controls by age, sex, and health screening year. Participants were followed from the index date until death or the end of 2019. The primary outcome was composite CVD [stroke or coronary heart disease (CHD)]; secondary outcomes included stroke, CHD, and all-cause mortality. LDL-C levels were categorized into clinically relevant strata. Adjusted hazard ratios (HRs) were estimated using Cox proportional hazards models, accounting for demographic, clinical, and lifestyle factors. Interaction terms assessed LDL-C level effect modification.</p><p><strong>Results: </strong>Among 15 385 patients with seropositive RA and 76 727 matched controls (mean age 55.4 years; 26.7% male), RA was associated with significantly increased risks of CVD [adjusted HR 1.33, 95% confidence interval (CI) 1.25-1.41], stroke (1.16, 1.08-1.26), CHD (1.49, 1.38-1.62), and all-cause mortality (1.93, 1.81-2.05), with no statistically significant interaction between RA status and LDL-C category for any outcome.</p><p><strong>Conclusion: </strong>In this large national cohort, seropositive RA was independently associated with increased cardiovascular event and all-cause mortality risks, regardless of LDL-C level. These findings suggest that conventional LDL-C-based risk stratification may be insufficient for patients with RA, and support broader risk management approaches.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149113891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of peripheral artery disease following ankylosing spondylitis, 2012-2023: a nationwide cohort study in South Korea.","authors":"Y Bae, M Jang, K-Y Bak, S R Jeon, W-S Shin, J Ahn, J H Park, H Jung","doi":"10.1080/03009742.2026.2722472","DOIUrl":"https://doi.org/10.1080/03009742.2026.2722472","url":null,"abstract":"<p><strong>Objective: </strong>Ankylosing spondylitis (AS) is a chronic inflammatory disease linked to systemic vascular complications. Evidence regarding the association between AS and peripheral artery disease (PAD) remains limited. We investigated whether patients with AS have an increased risk of PAD using a nationwide cohort in South Korea.</p><p><strong>Method: </strong>Using the Korean National Health Insurance Service database (2012-2023), we conducted a nationwide matched cohort study. Patients with AS were identified by at least two diagnoses of International Classification of Diseases, 10th Revision (ICD-10) code M45 within 1 year. Incident PAD was defined as at least one outpatient visit with ICD-10 code I73.9 after the index date. After a 3 year washout period, 2846 patients with AS and 28 460 matched controls were analysed. Risk was assessed using incidence rate ratios (IRRs) and Cox proportional hazards models.</p><p><strong>Results: </strong>During a mean follow-up of 4.1 years, PAD incidence was higher in patients with AS than in controls (23.6 vs 16.9 per 1000 person-years; IRR 1.40, 95% confidence interval 1.23-1.59). Females aged <60 years had the highest excess risk (IRR 1.77), followed by males aged ≥60 years (IRR 1.64). Kaplan-Meier curves showed lower PAD-free survival in patients with AS (log-rank p < 0.0001).</p><p><strong>Conclusion: </strong>AS was associated with an increased risk of PAD, particularly among younger females, highlighting the need for early vascular screening and tailored prevention strategies.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-11"},"PeriodicalIF":1.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of tofacitinib in polymyalgia rheumatica: a retrospective comparative study.","authors":"X Wang, D Feng, L Jia, L Xu","doi":"10.1080/03009742.2026.2722526","DOIUrl":"https://doi.org/10.1080/03009742.2026.2722526","url":null,"abstract":"<p><strong>Objective: </strong>Polymyalgia rheumatica (PMR) is a common inflammatory disorder in older adults, characterized by persistent muscle pain and stiffness. This study aimed to evaluate the efficacy and safety of tofacitinib as a potential therapeutic option in patients with PMR.</p><p><strong>Method: </strong>This single-centre retrospective study included 60 patients diagnosed with PMR between February 2021 and March 2025. Patients were categorized into three groups: tofacitinib monotherapy (n = 14), tofacitinib combined with prednisone (n = 20), and prednisone monotherapy (n = 26). The primary outcome was the change in the Polymyalgia Rheumatica Activity Score (PMR-AS) from baseline to month 6. Secondary outcomes included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), morning stiffness duration, elevation of upper limbs, physician- and patient-rated visual analogue scales (VAS), haemoglobin, platelet (PLT) and white blood cell counts, as well as 6 month changes in these parameters, cumulative prednisone dose, and incidence of adverse events.</p><p><strong>Results: </strong>After 6 months of treatment, all regimens produced significant within-group improvements in PMR-AS, ESR, VAS, haemoglobin, PLT, morning stiffness duration, and CRP levels (p < 0.01 for all). The mean changes in PMR-AS and other outcomes did not differ significantly among groups. Patients receiving tofacitinib combined with prednisone required lower daily and cumulative prednisone doses (p < 0.01). No serious adverse events were recorded during the 6 month follow-up.</p><p><strong>Conclusion: </strong>Tofacitinib-containing regimens were associated with improvement in PMR disease activity, and combination treatment was associated with lower prednisone exposure. These findings support further prospective evaluation of tofacitinib as a potential glucocorticoid-sparing strategy in PMR.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-9"},"PeriodicalIF":1.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of severe functional limitations and physical therapy use in patients with rheumatoid arthritis or axial spondyloarthritis: a multicentre cross-sectional study in the Netherlands.","authors":"A R Iken, L van Bodegom-Vos, Tpm Vliet Vlieland, F A van Gaalen, A M van Tubergen, W H Noort-van der Laan, R W Poolman, Mgj Gademan","doi":"10.1080/03009742.2026.2711489","DOIUrl":"https://doi.org/10.1080/03009742.2026.2711489","url":null,"abstract":"<p><strong>Objective: </strong>To inform implementation of a long-standing, personalized exercise therapy programme in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) and severe functional limitations, we estimated the prevalence of severe functional limitations and described current physical therapy (PT) use.</p><p><strong>Method: </strong>In a multicentre cross-sectional study, rheumatologists at 11 medical centres used a checklist to record severe functional limitations in consecutive outpatients with RA or axSpA. The same patients were invited to complete an online questionnaire on current or recent PT use, including duration where applicable.</p><p><strong>Results: </strong>Rheumatologists completed the checklist for 612 patients. Severe functional limitations were identified in 58/443 in RA (13%; 95% confidence interval 10-16) and 27/169 in axSpA (16%; 95% confidence interval 11-21). The online questionnaire was sent to 486 patients, of whom 251 (52%) responded (191 RA; 60 axSpA). Among respondents, 39/251 (16%) were classified by rheumatologists as having severe functional limitations. Among those who were severely limited, 13/39 (33%) reported individual long-term PT; among those without severe functional limitations, 46/212 (22%) reported individual long-term PT.</p><p><strong>Conclusion: </strong>Our study shows a mismatch between eligibility and current PT use: long-term PT appeared underused among patients with severe functional limitations and potentially overused among those without them. Non-recommended passive modalities were frequently used. A systematic implementation strategy is needed to facilitate the uptake of the evidence-based PT in clinical practice for patients with RA or axSpA and severe functional limitations.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifocal native septic arthritis limited to peripheral small joints caused by <i>Streptococcus pyogenes</i>.","authors":"K Ishiguro, Y Suda, M Kanaji, S Kaneko","doi":"10.1080/03009742.2026.2647539","DOIUrl":"10.1080/03009742.2026.2647539","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"380-382"},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Environmental and occupational factors in the aetiopathogenesis of systemic sclerosis: insights from a large multinational patient survey.","authors":"M Hughes, G Bandini, S Di Donato, Z H McMahan, S Bellando Randone, A Alunno, I Basinas, M van Tongeren, A Povey","doi":"10.1080/03009742.2026.2644688","DOIUrl":"10.1080/03009742.2026.2644688","url":null,"abstract":"<p><strong>Objective: </strong>Systemic sclerosis (SSc) is a rare and heterogeneous disease. SSc pathobiology is complex and it occurs in a genetically susceptible host. Our aim was to describe potential environmental and occupational exposures relevant to SSc.</p><p><strong>Method: </strong>An online survey was developed in English to collect detailed information about relevant current/past environmental and occupational exposures. Individuals with SSc were invited to participate through international patient associations and social media. Participation was voluntary and no identifiable information was collected. We used descriptive statistics to summarize our data.</p><p><strong>Results: </strong>In total, 478 evaluable individuals (93% female; 81% ≥ 51 years old) from 19 countries [mostly USA (68%) and UK (23%)] completed the survey. Concerning SSc subtype, 137 had diffuse and 178 limited cutaneous SSc; and around one-fifth mixed connective tissue disease/SSc overlap (n = 84). The majority had a long-established diagnosis of SSc (>10 years 50%, 5-10 years 20%). One-third were in active employment (full-time 23%, part-time 10%), 4.6% were self-employed, and 42% were retired. The most frequently reported current and past work-related exposures (reported by >10% of participants) included outdoor sun exposure, paint/varnishes/lacquers, weedkillers, wet work/cleaning agents, paint thinners/removers, biological agents, pesticides, solvents/degreasers, and ionizing radiation. Exposures previously implicated in SSc were also reported, including silica/quartz, PVC/plasticizers, vinyl chloride, and epoxy resins, although less frequently.</p><p><strong>Conclusio: </strong>We benchmark potential environmental and occupational factors in SSc. A novel finding was the identification of several important potential industrial/chemical agent exposures. These data could inform future SSc research concerning occupational/environmental triggers.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"344-351"},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin G and immunoglobulin A anti-Ro52 in plasma and saliva show little association with disease activity in patients with primary Sjögren's disease.","authors":"C L Dreyer, K B Norheim, M B Lauvsnes, Sja Johnsen, J H Mikkelsen, Cbf Andersen, B Deleuran, Mln Dahl","doi":"10.1080/03009742.2026.2654264","DOIUrl":"10.1080/03009742.2026.2654264","url":null,"abstract":"<p><strong>Objective: </strong>Primary Sjögren's disease (pSjD) is one of the most common autoimmune connective tissue diseases. Sicca symptoms are a hallmark of pSjD. Up to 80% of patients have immunoglobulin G (IgG) anti-Ro52 autoantibodies in their plasma. This study investigates the frequency of IgG and IgA anti-Ro52 autoantibodies in plasma and saliva from pSjD patients, and assess the associations between disease activity and autoantibody titers.</p><p><strong>Method: </strong>The study was conducted on a Norwegian cross-sectional SjD cohort (n = 113). IgA and IgG anti-Ro52 autoantibodies were measured in plasma and saliva by an indirect in-house enzyme-linked immunosorbent assay (ELISA). ELISA results were correlated with clinical data using relative risk and Spearman's correlation coefficients.</p><p><strong>Results: </strong>Measuring plasma, 73% of the cohort were positive for IgG anti-Ro52 and 47% for IgA anti-Ro52 autoantibodies. In saliva, 34% were positive for IgA anti-Ro52 and 17% for IgG anti-Ro52 autoantibodies. We observed an inverse correlation between plasma IgG anti-Ro52 autoantibodies and disease activity. Patients with a low plasma titre of IgG anti-Ro52 autoantibodies had a higher probability of reporting pain, as indicated by the EULAR Sjögren's Syndrome Patient Reported Index score (relative risk = 0.48, 95% confidence interval 0.29-0.80, p = 0.002). Furthermore, plasma IgA anti-Ro52 correlated significantly with the focus score.</p><p><strong>Conclusion: </strong>IgA and IgG anti-Ro52 autoantibodies in saliva and plasma showed an inverse correlation with disease activity but significant positive association with immune activity in patients with SjD. Our findings do not support the use of salivary IgA and IgG anti-Ro52 autoantibodies as biomarkers of disease activity in SjD.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"366-374"},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}